Pregabalin Capsule
Product Images NDC 70518-3597

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-3597). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Pregabalin 75 mg oral capsules packaging label by RemedyRepack Inc. The label indicates a quantity of 90 capsules and specifies prescription use (C-V). It also shows the National Drug Code 70518-3597-00, manufacturer Ascend Labs LLC, and storage instructions.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a factor adjustment for female patients. The formula is presented as a text panel with mathematical notation.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

A bar chart depicting responder rates (%) in two clinical studies, E1 and E3, comparing placebo to varying doses of pregabalin from 50 mg/day to 600 mg/day. The X-axis lists dosage groups and patient numbers, while the Y-axis shows responder rate percentages. Statistically significant increases versus placebo are marked with asterisks.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

A line graph showing median percent change from baseline in seizure reduction versus pregabalin dose (mg/day) across multiple studies labeled E1 BID, E2 TID, and E3 BID and TID. The graph shows increasing seizure reduction with higher doses, with significant p-values indicated at different dose points. The x-axis ranges from 0 (placebo) to 600 mg/day, and the y-axis shows seizure reduction values from 0 to 60 percent.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph illustrating the percent of patients improved versus percent improvement in pain from baseline. It compares the effects of Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken three times daily against a placebo, showing trends of patient improvement in pain levels across these treatments.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line graph showing the percent of subjects improved over time, comparing Pregabalin and Placebo treatments. The x-axis represents the percent improved from baseline to Week 12 BOCF, while the y-axis indicates the percent of subjects improved. Two lines depict the response rates for Pregabalin (higher line) and Placebo (lower line).*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line graph comparing the percent of subjects improved over time from baseline to Week 16 post baseline cognitive function (BOCF). The horizontal axis shows percent improved from baseline to Week 16 BOCF, and the vertical axis shows the percent of subjects improved. The graph includes two lines representing Pregabalin and Placebo groups, with Pregabalin showing a higher percent of subject improvement overall.*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line graph representing the percentage of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day to placebo, showing two distinct curves on the plot. The y-axis shows percent of patients improved and the x-axis shows percent improvement in pain from baseline.*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

Line graph depicting percent of patients improved versus percent improvement in pain from baseline. The graph compares outcomes for Pregabalin at 75 mg, 150 mg, and 300 mg taken twice a day, along with a placebo group, showing varying degrees of patient improvement in pain.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. The graph compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing the distribution of patient responses at different pain improvement percentages.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. The graph compares three lines representing Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating differences in patient improvement over a range of pain improvement percentages.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line graph illustrating percent of patients improved versus percent improvement in pain from baseline. The graph compares pregabalin daily doses of 300 mg, 450 mg, and 600 mg with a placebo, showing trends in patient improvement across varying pain reduction percentages.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A Kaplan-Meier survival curve comparing the estimated percentage of subjects without loss to follow-up or response (LTR) over 180 days for Pregabalin versus placebo groups. The solid line represents Pregabalin, and the dashed line represents placebo, showing higher retention rates in the Pregabalin group across the study period.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure of pregabalin, showing its molecular configuration with amine (NH2) and carboxylic acid (CO2H) groups attached to a branched carbon backbone.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.